Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial

PURPOSE. The initial report from the Programme Action Concertée Sein (PACS) PACS01 trial demonstrated a benefit at 5 years for disease-free survival (DFS) and overall survival (OS) rates with the sequential administration of docetaxel after FEC100 (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Coudert, Bruno, Asselain, Bernard, Campone, Mario, Spielmann, Marc, Machiels, Jean-Pascal, Pénault-Llorca, Frédérique, Serin, Daniel, Lévy, Christelle, Romieu, Gilles, Canon, Jean-Luc, Orfeuvre, Hubert, Piot, Gilles, Petit, Thierry, Jerusalem, Guy, Audhuy, Bruno, Veyret, Corinne, Beauduin, Marc, Eymard, Jean-Christophe, Martin, Anne-Laure, Roché, Henri
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2012
Teme:
Breast Cancer
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399644/
https://ncbi.nlm.nih.gov/pubmed/22610153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0442
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items